Features - ViiV Healthcare, Genetics

Filter

Current filters:

ViiV HealthcareGenetics

Popular Filters

1 to 25 of 78 results

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

Interview: AstraZeneca’s oncology expert Susan Galbraith on the company’s exciting pipeline

11-04-2014

The full year report from Anglo-Swedish drug major AstraZeneca (LSE: AZN) in February was full of optimism.…

AstraZenecaInterviewsIressaOncologyPharmaceuticalUK

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

EGA Biosimilars: Prescribers must be encouraged to use biosimilars

07-04-2014

Uptake of biosimilars in Europe has increased as a result of member states’ policies, according to…

BiosimilarsEuropeFilgrastimInterviewsMarkets & MarketingRegulationSandoz

EGA Biosimilars: European monitoring and global business opportunities

EGA Biosimilars: European monitoring and global business opportunities

07-04-2014

The spotlight was on the European uptake of biosimilars at the European Generic medicines Association’s…

BiosimilarsEuropeGlobalInterviewsMarkets & Marketing

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

ViiV Healthcare grants licence to Medicines Patent Pool to improve access to Tivicay

02-04-2014

Viiv Healthcare, the HIV/AIDS joint venture of UK pharma giant GlaxoSmithKline, US drugmaker Pfizer and…

Anti-viralsGlobalPharmaceuticalPricingTivicayViiV Healthcare

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

Executive Q&A: Epigenomics’ chief executive Dr Thomas Taapken

01-04-2014

The Pharma Letter interviewed chief executive Dr Thomas Taapken about Epigenomics’ lead product, increasing…

BiotechnologyEpi proColonEpigenomicsGermanyInterviewsOncology

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

Interview: Arnaud Grunwald of Model N on taking a holistic approach to revenue management

20-03-2014

As health care budgets are squeezed worldwide and access issues continue to make the headlines, the price…

GlobalInterviewsPharmaceuticalPricing

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

Executive Q&A: ADC Therapeutics’ chief executive Michael Forer

19-03-2014

In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline…

ADC TherapeuticsBiotechnologyInterviewsNorthern EuropeOncology

Executive Q&A: Fibrotech's chief executive Darren Kelly

Executive Q&A: Fibrotech's chief executive Darren Kelly

18-03-2014

The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product,…

AustraliaBiotechnologyFibrotechInterviewsNephrology and Hepatology

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

Pharma Summit: Sanofi president Elias Zerhouni calls for harmony and evolution in pharma

14-03-2014

Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias…

EuropeHealthcareInterviewsPharmaceuticalSanofi

Pharma Summit: Rethinking the future – new business models for pharma

Pharma Summit: Rethinking the future – new business models for pharma

14-03-2014

The way pharma works needs to change with an increasing focus on collaborations, sharing data and access…

HealthcareInterviewsLundbeckPfizerPharmaceuticalPricingUK

Oxford Gene Technology acquires Cytocell to expand genomics offering

Oxford Gene Technology acquires Cytocell to expand genomics offering

04-03-2014

Genetic research company Oxford Gene Technology has acquired Cambridge-based Cytocell, a leading provider…

BiotechnologyGeneticsMergers & AcquisitionsOxford Gene TechnologyUK

Viiv Healthcare comes out top in global survey of pharma industry reputations

14-02-2014

An independent global study has recorded the latest impressions of the corporate reputation of the world’s…

AbbVieGlobalPharmaceuticalResearchViiV Healthcare

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Exclusive: Changing pharma marketplace means new dynamics to deal with, says Mundipharma executive

11-02-2014

The pharmaceutical market is changing, says Georg Toufar, chief marketing officer of Mundipharma International,…

InterviewsManagementMarkets & MarketingMundipharmaPharmaceutical

Putting patients first is a win-win situation

Putting patients first is a win-win situation

07-02-2014

Here's our take on the week's top stories.

Anti-viralsPharmaceuticalTivicayUKViiV Healthcare

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

Faster, better, safer: How clinical trials can be transformed by Equivital wearable technology

04-02-2014

A UK-based mobile human monitoring company is making waves in health care as it aims to revolutionize…

BiotechnologyInterviewsPharmaceuticalResearchUK

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

IN FOCUS: Viiv Healthcare’s Tivicay offers new HIV treatment option for patients

03-02-2014

Global HIV company Viiv Healthcare has launched its first new treatment option for people with HIV today.

Anti-viralsAtriplaInterviewsIsentressPharmaceuticalPrezistaRegulationResearchTivicayUKViiV Healthcare

EXPERT VIEW: Pharmaceutical firms “can’t keep ignoring information risk”

28-01-2014

Knowledge is the lifeblood of the pharmaceutical sector. From raw experimental data to complex chemical…

EuropeInterviewsManagementPharmaceutical

UCB launches online search for rare phenotypes

UCB launches online search for rare phenotypes

28-01-2014

Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an online search to find rare phenotypes…

GeneticsGlobalPharmaceuticalRare diseasesResearchUCB

ViiV Healthcare’s new HIV medicine Tivicay is approved in Europe

21-01-2014

The European Commission has approved Tivicay (dolutegravir) made by Viiv Healthcare for use in combination…

Anti-viralsEuropePharmaceuticalResearchTivicayViiV Healthcare

Tivicay set to become leading HIV treatment by 2016

Tivicay set to become leading HIV treatment by 2016

15-01-2014

Antiretroviral drug Tivicay (dolutegravir) is set to become the leading integrase inhibitor for the treatment…

Anti-viralsAsia-PacificEuropeIsentressJanssenMarkets & MarketingMerck & CoPharmaceuticalPrezistaTivicayUSAViiV Healthcare

1 to 25 of 78 results

Back to top